597 Preliminary results from LuCa-MERIT-1, a first-in-human Phase I trial evaluating the fixed antigen RNA vaccine BNT116 in patients with advanced non-small cell lung cancer

• Patrick Forde,
• Neru Munshi,
• Ugur Sahin,
• Oezlem Tuereci,
• Akin Atmaca,
• Petra Rietschel,
• Dániel Deme,
• Bala Öven,
• Erdem Göker,
• Istvan Lang,
• Patrick Brück,
• Michael Wenger,
• Thomas Schell,
• Kezi Ünsal-Kaçmaz,
• Janet Markman,
• Huyuan Yang

Affiliations

Patrick Forde

Aff3 grid.21107.350000000121719311Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore MD USA

Neru Munshi

EMD Serono Research & Development Institute, Inc, Billerica, Massachusetts, USA; a business of Merck KGaA, Darmstadt, Germany

Ugur Sahin

6BioNTech SE, Mainz, Rheinland-Pfalz, Germany

Oezlem Tuereci

9BioNTech SE, Mainz, Germany

Akin Atmaca

1 Oncology and Hematology, Krankenhaus Nordwest, Frankfurt, Germany

Petra Rietschel

10Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA

Dániel Deme

1Clinexpert Ltd. Phase I Center Gyöngyös (Bugát Pál Hospital), Gyöngyös, Hungary

Bala Öven

2Yeditepe University Faculty of Medicine, Istanbul, Turkey

Erdem Göker

3Ege University, Izmir, Turkey

Istvan Lang

4PRA Health Sciences, Budapest, Hungary

Patrick Brück

6BioNTech SE, Mainz, Rheinland-Pfalz, Germany

Michael Wenger

6BioNTech SE, Mainz, Rheinland-Pfalz, Germany

Thomas Schell

8BioNTech SE, Planegg, Germany

Kezi Ünsal-Kaçmaz

9BioNTech US, Cambridge, MA, USA

Janet Markman

9BioNTech US, Cambridge, MA, USA

Huyuan Yang

11BioNTech US, Cambridge, MA, USA